Efficacy and Safety of Generic Dasatinib As First-Line Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase: Final Analysis with 2-Year Follow-up
第一作者单位:[1]Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Hematol, Hangzhou, Peoples R China[2]Zhejiang Univ Med, Affiliated Hosp 1, Hangzhou, Peoples R China
推荐引用方式(GB/T 7714):
Jin Jie,Meng Li,Yu Wenjuan,et al.Efficacy and Safety of Generic Dasatinib As First-Line Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase: Final Analysis with 2-Year Follow-up[J].BLOOD.2021,138:doi:10.1182/blood-2021-150197.
APA:
Jin, Jie,Meng, Li,Yu, Wenjuan,Liu, Peng,Du, Xin...&Wang, Weiguang.(2021).Efficacy and Safety of Generic Dasatinib As First-Line Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase: Final Analysis with 2-Year Follow-up.BLOOD,138,
MLA:
Jin, Jie,et al."Efficacy and Safety of Generic Dasatinib As First-Line Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase: Final Analysis with 2-Year Follow-up".BLOOD 138.(2021)